<<snip>>
resulting in long-lasting transfusion-free survival
<<snip>>
Correction of anemia in a transfusion-dependent patient with primary
myelofibrosis receiving iron chelation therapy with deferasirox
(Exjade®, ICL670)
Authors: Di Tucci, Anna Angela1; Murru, Roberta1; Alberti, Daniele2;
Rabault, Bertrand2; Deplano, Simona1; Angelucci, Emanuele1
Source: European Journal of Haematology, Volume 78, Number 6, June
2007, pp. 540-542(3)
Publisher: Blackwell Publishing
Abstract:
Transfusional iron overload in patients with chronic anemias can
result in multiple organ failure. Experience in the management of iron
overload in patients with myelodysplastic syndromes is limited, as
many do not receive chelation therapy due to short-life expectancy and
the difficulties associated with the administration of the current
reference standard chelator, deferoxamine. There have, however, been
some reports of reduced transfusion requirement associated with
chelation therapy in patients with myelodysplastic syndromes and
myelofibrosis. Here, we discuss a patient with primary myelofibrosis
and related transfusion-dependent anemia who received chelation
therapy with the once-daily oral iron chelator, deferasirox. In
addition to the reduced iron levels, the patient demonstrated an
unexpected reduction in blood transfusion requirement, ultimately
resulting in long-lasting transfusion-free survival.
Keywords: myelofibrosis; iron overload; chelation
Document Type: Research article
DOI: 10.1111/j.1600-0609.2007.00840.x
Affiliations: 1: Unità Operativa Ematologia e Centro Trapianti Midollo
Osseo, Ospedale Oncologico `Armando Businco', Cagliari, Italy 2:
Novartis Pharma AG, Basel, Switzerland
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk